Quest Diagnostics (NYSE:DGX) Given New $260.00 Price Target at Mizuho

Quest Diagnostics (NYSE:DGX) had its target price increased by Mizuho from $235.00 to $260.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an outperform rating on the medical research company’s stock.

A number of other brokerages have also recently issued reports on DGX. Barclays upped their target price on Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, July 9th. Robert W. Baird boosted their target price on shares of Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday. Truist Financial upped their price target on shares of Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a report on Friday. Finally, UBS Group reaffirmed a “neutral” rating and issued a $232.00 price target on shares of Quest Diagnostics in a research report on Friday. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Quest Diagnostics has a consensus rating of “Moderate Buy” and an average target price of $231.73.

Quest Diagnostics Stock Performance

DGX stock opened at $228.05 on Friday. The firm has a 50 day moving average of $203.23 and a two-hundred day moving average of $197.59. Quest Diagnostics has a 12 month low of $165.78 and a 12 month high of $237.78. The company has a market capitalization of $25.24 billion, a price-to-earnings ratio of 24.21, a P/E/G ratio of 2.61 and a beta of 0.58. The company has a quick ratio of 1.08, a current ratio of 1.59 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The business had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same quarter last year, the firm earned $2.62 EPS. Quest Diagnostics’s revenue for the quarter was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, equities analysts anticipate that Quest Diagnostics will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th were issued a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. The ex-dividend date of this dividend was Wednesday, July 8th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.52%.

Insider Buying and Selling

In related news, SVP Karthik Kuppusamy sold 8,147 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the transaction, the senior vice president directly owned 13,510 shares of the company’s stock, valued at $2,702,000. This trade represents a 37.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the sale, the chief executive officer owned 132,423 shares in the company, valued at $25,708,601.22. This represents a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.88% of the company’s stock.

Institutional Trading of Quest Diagnostics

Institutional investors have recently made changes to their positions in the business. Norges Bank bought a new stake in Quest Diagnostics in the fourth quarter valued at about $229,522,000. Boston Partners lifted its stake in Quest Diagnostics by 32.8% during the third quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after purchasing an additional 997,033 shares during the period. EdgePoint Investment Group Inc. boosted its holdings in Quest Diagnostics by 95.5% during the fourth quarter. EdgePoint Investment Group Inc. now owns 1,661,072 shares of the medical research company’s stock valued at $288,246,000 after purchasing an additional 811,320 shares in the last quarter. UBS Group AG raised its holdings in shares of Quest Diagnostics by 67.8% in the 4th quarter. UBS Group AG now owns 1,114,451 shares of the medical research company’s stock worth $193,391,000 after buying an additional 450,161 shares in the last quarter. Finally, Bank of America Corp DE grew its position in Quest Diagnostics by 36.3% in the second quarter. Bank of America Corp DE now owns 1,599,602 shares of the medical research company’s stock valued at $287,337,000 after acquiring an additional 426,399 shares during the period. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics News Roundup

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
• Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
• Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.